Sarep­ta halts its golodirsen Duchenne MD study in UK af­ter pa­tient ex­pe­ri­ences ad­verse event

Sarep­ta said this morn­ing that it has halt­ed dos­ing its Duchenne mus­cu­lar dy­s­tro­phy drug golodirsen at all its UK sites af­ter one of the pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA